Details for Patent: 7,964,202

Summary for Patent: 7,964,202

Title:	Method for treatment of common acne
Abstract:	Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4° C. to 40° C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress τ for a given rate gradient γ and which measure a rate gradient γ for a given shear stress τ, the yield value (τ0) being extrapolated visually or by calculation.
Inventor(s):	Sandrine Orsoni, Nathalie Willcox
Assignee:	Galderma Research and Development SNC
Application Number:	US12/076,859
Patent Claim Types: see list of patent claims	Use; Composition;

US Patent 7,964,202: Adapalene-Benzoyl Peroxide Gel Claims, Expiry, Litigation and Generic Risk

US Patent 7,964,202 protects a narrowly defined once-daily acne product combining 0.1% adapalene, 2.5% dispersed benzoyl peroxide and 4% of a specified polymeric gelling system. The patent covers both treatment use and a packaged product. Its commercial relevance is tied to the adapalene/benzoyl peroxide product marketed as Epiduo, although infringement depends on the precise formulation, manufacturing composition and label of each competing product.

The patent has a composition-specific scope. It does not broadly cover every adapalene and benzoyl peroxide formulation. The principal limitations are the active concentrations, the once-daily acne indication, the aqueous-gel dosage form and the 4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 system.

What drug does US Patent 7,964,202 protect?

US Patent 7,964,202 protects a topical aqueous gel containing adapalene and benzoyl peroxide for once-daily treatment of common acne. The patent is associated with Galderma’s adapalene/benzoyl peroxide product platform and the composition used in Epiduo-type products.

Element	Claim requirement
Therapeutic use	Treatment of common acne
Administration	Once daily
Dosage form	Physiologically acceptable aqueous gel
Adapalene	0.1% by total composition weight
Benzoyl peroxide	2.5%, dispersed
Gelling system	4% acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80
Active-ingredient limitation	Adapalene and benzoyl peroxide are the recited anti-acne actives
Claim types	Method of treatment and packaged product
Product claim packaging	Container holding the claimed gel

The patent’s technical focus is the combination of two chemically different acne actives in a stable aqueous gel. Adapalene is a topical retinoid. Benzoyl peroxide is an oxidizing antimicrobial and keratolytic active. The gelling system controls suspension, rheology, spreadability and physical stability.

What are the independent claims in US Patent 7,964,202?

Claim 1: Once-daily acne-treatment method

Claim 1 requires all of the following:

1. A subject in need of acne treatment.
2. Administration once daily.
3. A physiologically acceptable aqueous gel.
4. Treatment of common acne.
5. Anti-acne actives consisting of 0.1% adapalene and/or an acceptable adapalene salt.
6. 2.5% dispersed benzoyl peroxide.
7. 4% of the specified acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 gelling agent.
8. Concentrations calculated against total gel weight.

This is a method claim. It is potentially infringed by use of a qualifying product according to a once-daily acne-treatment indication, even if the manufacturer does not itself administer the product. In an ANDA context, the proposed label and intended use are central to the analysis.

Claim 2: Packaged product

Claim 2 requires:

• A container; and
• The same once-daily aqueous gel composition inside that container.

The container limitation is unlikely to be commercially difficult to satisfy. A tube, pump, bottle or other retail package containing the claimed gel would ordinarily meet the structural requirement if the composition limitations are also met.

Claim 2 is important because it creates product-level exposure independent of a particular patient’s use. A manufacturer, distributor or seller may face a direct-infringement theory based on making, offering for sale or selling the packaged product.

How narrow is the 7,964,202 patent claim scope?

The claims are narrower than a general patent on adapalene plus benzoyl peroxide. The following limitations materially constrain claim scope:

Exact or near-exact active concentrations

The claims recite 0.1% adapalene and 2.5% benzoyl peroxide. A product using adapalene 0.3%, benzoyl peroxide 2.5%, or another benzoyl peroxide concentration may avoid literal infringement, subject to doctrine-of-equivalents issues and other patent claims.

The absence of “about” before the percentages creates a potential claim-construction issue. Courts may consider manufacturing tolerances and pharmaceutical assay variability, but a materially different concentration creates a stronger noninfringement position.

Specific gelling-agent system

The claim does not merely require “a polymeric gelling agent.” It identifies a particular mixture:

• Acrylamide sodium acryloyldimethyltaurate copolymer;
• Isohexadecane; and
• Polysorbate 80.

This is commonly associated with a pre-formulated rheology modifier such as Sepineo P 600. A competing product using carbomer, cellulose derivatives, poloxamer or a different polymer system may not literally satisfy the claim.

The analysis must focus on the ingredients actually present in the final formulation. Substituting a different commercial grade or using the polymer without the same carrier system could affect infringement, depending on the claim construction and product composition.

Aqueous-gel requirement

A nonaqueous cream, anhydrous suspension, lotion or emulsion may fall outside the literal scope of the claims. The formulation must be evaluated by its physical and chemical characteristics rather than by its marketing description.

Once-daily treatment limitation

Claim 1 is linked to once-daily administration. A product labeled only for twice-daily use may create a stronger defense to the method claim, but it would not necessarily avoid claim 2 if the product itself meets the composition and packaging limitations.

“Consisting of” limitation for anti-acne actives

The claim states that the anti-acne actives consist of adapalene and benzoyl peroxide. This language may limit the claim to those recited anti-acne active ingredients. It does not necessarily prohibit every inactive excipient, preservative, antioxidant or processing aid because the broader composition language separately uses “comprising.”

A product containing salicylic acid, clindamycin, dapsone or another additional acne active could present a claim-scope issue. Whether the additional ingredient is an “anti-acne active” under the claim would depend on the evidence and claim construction.

When does US Patent 7,964,202 expire?

The patent’s ordinary US term is calculated from the earliest relevant nonprovisional filing date in the patent family. Public patent records identify the relevant US application filing date as March 17, 2006, with priority claims associated with the earlier development of the formulation. On a standard 20-year calculation, the nominal expiration date is March 17, 2026, subject to any patent-term adjustment, terminal disclaimer or other USPTO term event.[1]

Milestone	Date or status
Earliest relevant development priority	2005 family priority
US nonprovisional filing	March 17, 2006
US patent issue	June 21, 2011
Nominal 20-year term endpoint	March 17, 2026
Patent-term adjustment	Must be confirmed from the USPTO patent record
Patent-term extension	No extension is established by the claim text alone
Post-expiry enforceability	Depends on the recorded expiration date and any applicable term adjustment

The critical commercial point is that the patent’s expected protection window is near its statutory endpoint. A precise freedom-to-operate conclusion requires the USPTO continuity and patent-term records, not only the issue certificate or the front-page filing data.

What is the Orange Book status of US Patent 7,964,202?

The relevant regulatory product is Epiduo gel, containing adapalene 0.1% and benzoyl peroxide 2.5%. FDA-approved labeling identifies Epiduo as a topical prescription treatment for acne vulgaris in patients aged 9 years and older.[2]

The Orange Book is the relevant FDA source for listed patents and exclusivity associated with an approved drug product. A listed patent can support a Paragraph IV certification and an infringement action under the Hatch-Waxman framework.[3]

Regulatory issue	Analysis
Reference product	Epiduo gel
Active ingredients	Adapalene and benzoyl peroxide
Strength	0.1% / 2.5%
Dosage form	Topical gel
FDA pathway for generics	ANDA
Relevant patent challenge	Paragraph IV certification
New chemical entity risk	Limited because adapalene and benzoyl peroxide were previously approved actives
Exclusivity type	Patent protection and any product-specific FDA exclusivity are separate questions

FDA approval of a generic does not itself establish that all listed patents are invalid or unenforceable. An ANDA applicant may obtain approval after patent expiry, after a successful Paragraph IV challenge, after a settlement date, or through another statutory pathway.

How can generic manufacturers challenge this patent?

A generic applicant seeking approval for an equivalent adapalene/benzoyl peroxide gel may file a Paragraph IV certification if it asserts that the patent is invalid, unenforceable or not infringed. The reference product’s listing and the ANDA applicant’s proposed label determine the procedural framework.

Likely noninfringement positions

A challenger could argue that its product:

• Uses a different gelling agent;
• Does not contain the claimed 4% polymer premix;
• Uses a different adapalene concentration;
• Uses a different benzoyl peroxide concentration;
• Is not labeled for once-daily use;
• Is not an aqueous gel;
• Contains a formulation that does not include the claimed polymer components in the claimed proportions.

The strongest design-around route is likely a formulation change that avoids the named gelling system while preserving suspension and stability.

Potential invalidity positions

A Paragraph IV challenger could raise:

• Anticipation based on an earlier adapalene/benzoyl peroxide formulation;
• Obviousness based on combining known acne actives with known aqueous-gel excipients;
• Lack of written description or enablement for the claimed formulation;
• Indefiniteness concerning the identity and concentration of the gelling system;
• Claim-construction disputes over “consisting of,” “dispersed,” “once-daily” and “4%.”

The patent’s prosecution history would be important. If the claims were narrowed to the 4% gelling system to overcome prior art, prosecution estoppel could reduce the patentee’s ability to rely on equivalents for alternative polymers or concentrations.

What patent litigation affects adapalene and benzoyl peroxide products?

The principal litigation risk is an ANDA case brought after a Paragraph IV notice. The usual plaintiff would be the NDA holder or patent owner, and the defendants would be the generic applicant and potentially its corporate affiliates.

A litigation assessment should separate three questions:

1. Is the patent listed for the reference product?
2. Did the generic applicant certify under Paragraph IV?
3. Was an infringement action filed within the statutory 45-day period?

A patent listing alone does not prove that litigation was filed. A court docket, FDA Orange Book entry and ANDA notice must be reviewed together.

The litigation theories most likely to matter for this patent are formulation testing, polymer identity, concentration measurement and proposed labeling. Laboratory evidence may determine whether a generic formulation contains the claimed 4% gelling agent. The proposed label may determine whether the once-daily method claim is implicated.

Are there settlement agreements for generic Epiduo?

Settlement terms in pharmaceutical patent cases may include:

• A license allowing entry before patent expiry;
• A fixed generic launch date;
• A supply or authorized-generic arrangement;
• A covenant not to sue;
• Restrictions on formulation or labeling;
• Acceleration provisions tied to another challenger.

A settlement does not necessarily eliminate the patent. It may instead establish a private launch date earlier than the statutory expiration date. Any conclusion about an Epiduo settlement should be based on a filed court agreement, FTC review, SEC disclosure or other primary record. The patent number alone does not establish settlement terms.

What other patents may protect Epiduo or competing formulations?

US Patent 7,964,202 should be analyzed as one layer of a larger product estate.

Composition patents

These cover the combination of adapalene and benzoyl peroxide, specific concentrations, aqueous gels and stabilizing excipients. They are the most directly relevant patents for a generic seeking the same formulation.

Formulation patents

Formulation patents may cover:

• Specific polymeric gelling systems;
• Suspension stability;
• Particle-size control;
• Reduced irritation;
• Improved spreadability;
• Packaging compatibility;
• Solubilization or dispersion techniques;
• Preservative and antioxidant systems.

A formulation that avoids the 7,964,202 polymer limitation may still encounter a later or separate formulation patent.

Method-of-use patents

Method claims may cover:

• Once-daily administration;
• Treatment of acne vulgaris;
• Use in specified age groups;
• Reduced irritation;
• Improved tolerability;
• Treatment protocols involving titration or concurrent skin care.

An ANDA applicant may need to assess label carve-outs under section viii as well as Paragraph IV certifications. A carve-out is effective only if the omitted indication or dosing instruction removes the patented use from the proposed label and actual intended use.

Epiduo Forte and higher-strength adapalene products

Epiduo Forte contains adapalene 0.3% and benzoyl peroxide 2.5%, rather than the 0.1% adapalene strength recited in these claims. It should be treated as a separate product and patent analysis. A patent covering 0.3% adapalene does not automatically extend the scope of US 7,964,202.

Is biosimilar risk relevant to US Patent 7,964,202?

No. Biosimilar risk is not the appropriate framework because adapalene and benzoyl peroxide are small-molecule active ingredients. A competing product would normally proceed through the ANDA pathway as a generic drug, not through the biosimilar pathway under the Public Health Service Act.[3]

The principal regulatory risks are:

• ANDA patent certifications;
• Pharmaceutical equivalence;
• Bioequivalence or comparative clinical performance;
• Formulation differences;
• Labeling restrictions;
• Orange Book patent disputes.

How strong is the patent estate for adapalene and benzoyl peroxide?

The 7,964,202 patent is technically specific but commercially important.

Strength factor	Assessment
Commercial relevance	High for the 0.1%/2.5% Epiduo formulation
Claim breadth	Narrow to moderate
Composition specificity	High
Design-around potential	Meaningful, particularly through a different gelling system
Method-claim exposure	Dependent on once-daily labeling and use
Product-claim exposure	Stronger if the exact formulation is packaged and sold
Remaining term	Near the nominal March 17, 2026 endpoint
Biosimilar barrier	Not applicable
Generic challenge route	ANDA with Paragraph IV or post-expiry launch

The patent is stronger against a copycat formulation that reproduces the claimed gelling system than against a competitor that changes the polymer vehicle. The product claim gives the patent holder a broader enforcement tool than the method claim because it does not require proof of actual patient administration.

What generic launch scenarios exist for Epiduo?

Launch after patent expiry

A generic applicant may wait until the recorded patent term ends. This minimizes litigation risk but delays market entry and may forfeit first-filer advantages.

Paragraph IV launch

A first Paragraph IV applicant may seek approval before expiry by asserting invalidity or noninfringement. The NDA holder may file suit, triggering the statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court events.[3]

Formulation design-around

A generic may develop an aqueous adapalene/benzoyl peroxide gel using a different gelling system. This route reduces literal infringement risk but creates separate development and regulatory comparability work.

Label carve-out

If the patent’s relevant limitation is a patented use or dosing instruction, an applicant may attempt a section viii statement and omit the protected use. This option is less useful where the product claim independently covers the packaged formulation.

What geographic coverage does US Patent 7,964,202 provide?

The patent is enforceable only in the United States. Corresponding applications in Europe, Canada, Japan or other jurisdictions must be assessed separately because:

• Claim language differs by country;
• Patent-term calculations differ;
• Opposition or invalidity proceedings may alter foreign rights;
• Regulatory exclusivity is jurisdiction-specific;
• Settlement and license terms may vary by territory.

A US patent does not block manufacture, sale or use outside the United States unless another jurisdiction has a corresponding enforceable right.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barrier is reproducing the claimed physical composition without using the claimed polymer system. A product may have the same active ingredients and concentrations but avoid the claim if its rheology modifier, carrier system or final composition differs.

The principal evidence categories are:

• Full qualitative and quantitative composition;
• Supplier specifications for the polymer premix;
• Batch records;
• Finished-product assay;
• Rheology and particle-size data;
• Stability data;
• Labeling and promotional materials;
• ANDA patent certifications;
• Orange Book listings;
• Patent prosecution history.

A freedom-to-operate review should test the finished product, not only the formulation target. Manufacturing aids or raw-material names may obscure whether the final product contains the claimed components.

Key Takeaways

• US Patent 7,964,202 covers a once-daily aqueous acne gel containing 0.1% adapalene, 2.5% dispersed benzoyl peroxide and 4% of a specified polymeric gelling system.
• Claim 1 is a method claim tied to once-daily treatment of common acne.
• Claim 2 covers a container holding the claimed gel and may provide stronger product-level enforcement.
• The patent does not broadly cover every adapalene/benzoyl peroxide product.
• The named gelling system is the principal design-around limitation.
• Epiduo is the key reference product associated with the claimed active combination and strength.
• Generic competition proceeds through the ANDA pathway, with Paragraph IV, section viii and post-expiry strategies available depending on the proposed formulation and label.
• Biosimilar analysis is not relevant because the products contain small-molecule actives.
• The nominal patent term endpoint is March 17, 2026, subject to the official USPTO patent-term record.
• Orange Book listings, continuation patents, later formulation patents and litigation settlements must be reviewed separately from this patent.

FAQs

Does using the same adapalene and benzoyl peroxide strengths automatically infringe US 7,964,202?

No. The product must also satisfy the aqueous-gel, gelling-agent, 4% concentration and other claim limitations. Matching only the active strengths is insufficient for literal infringement.

Can a generic avoid the patent by replacing Sepineo P 600?

Potentially. Replacing the claimed acrylamide sodium acryloyldimethyltaurate copolymer/isohexadecane/polysorbate 80 system with a materially different gelling system may avoid literal infringement, although equivalents and other patents must be assessed.

Does the patent cover Epiduo Forte?

The claims supplied here recite 0.1% adapalene. Epiduo Forte uses 0.3% adapalene and requires a separate patent and regulatory analysis.

Is a cream covered by the patent?

Not necessarily. The claims require an aqueous gel. A cream, lotion or other dosage form may fall outside the literal claims unless its formulation is legally characterized as an aqueous gel.

Can a generic launch before March 2026?

Possibly, through a successful Paragraph IV challenge, a license or settlement, a noninfringing formulation, or another legally available pathway. Patent expiry alone is not the only route to launch.

References

1. United States Patent and Trademark Office. (2011). U.S. Patent No. 7,964,202, adapalene and benzoyl peroxide aqueous gel composition. U.S. Department of Commerce.

2. U.S. Food and Drug Administration. (2023). Epiduo (adapalene and benzoyl peroxide) gel, 0.1%/2.5%: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Code, 35 U.S.C. §§ 154, 271(e), 282.

6. U.S. Code, 21 U.S.C. § 355(j).

Drugs Protected by US Patent 7,964,202

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,964,202

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 16747	Dec 21, 2001

International Family Members for US Patent 7,964,202

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1458369		CA 2008 00029	Denmark
European Patent Office	1458369		08C0024	France
European Patent Office	1458369		SPC/GB10/005	United Kingdom
European Patent Office	1458369		C01458369/01	Switzerland
European Patent Office	1458369		380	Finland
European Patent Office	1458369		SZ 31/2008	Austria